Transforming the healthcare utilisation review process Newsletter Article 17 February 2013 Pages: 2 - 2
Influencing prescribing with drug use evaluation Jo BarnesTracey Langsdale Newsletter Article 17 February 2013 Pages: 3 - 4
QOL, costs and insurance - a ‘tragic irony’ in mental health Newsletter Article 17 February 2013 Pages: 4 - 4
Australia’s experience with pharmacoeconomic guidelines Newsletter Article 17 February 2013 Pages: 5 - 5
Market reforms not the key to improving US healthcare Newsletter Article 17 February 2013 Pages: 6 - 6
Smaller hospitals can ‘cost-justify’ antibacterial services Newsletter Article 17 February 2013 Pages: 7 - 7
Cost implications of medication-related problems - US study data Newsletter Article 17 February 2013 Pages: 8 - 8
Paroxetine vs imipramine for treatment of depression Newsletter Article 17 February 2013 Pages: 8 - 9
Ticarcillin/clavulanic acid switch programme cost saving Newsletter Article 17 February 2013 Pages: 9 - 9
Highlighting the economic liability of schizophrenia Newsletter Article 17 February 2013 Pages: 10 - 10
Home IV antibacterial service for CF reduces costs by 45% Newsletter Article 17 February 2013 Pages: 12 - 12
Is utilisation review effective in a health insurance plan? Newsletter Article 17 February 2013 Pages: 12 - 12
Comparing the effects of 4 antihypertensives on QOL Newsletter Article 17 February 2013 Pages: 13 - 13
Link between neuropsychological function and QOL in epilepsy Newsletter Article 17 February 2013 Pages: 14 - 14
Half of US prescription drug sales paid by managed care Newsletter Article 17 February 2013 Pages: 15 - 15
Patterns of care changing in psychiatric health systems Newsletter Article 17 February 2013 Pages: 16 - 16